Aravax

Aravax is a clinical stage biotechnology company dedicated to revolutionising the treatment of food allergy by developing next-generation, disease-modifying peptide-based immunotherapies that are safer and more convenient than existing approaches. Its lead programme is PVX108, in clinical development for the treatment of peanut allergy.